{"Niraparib,": [0], "an": [1], "inhibitor": [2], "of": [3, 27, 32, 37, 128, 132, 221, 249, 258, 301, 306], "poly(adenosine": [4], "diphosphate": [5], "[ADP]-ribose)": [6], "polymerase": [7], "(PARP),": [8], "has": [9], "been": [10], "associated": [11], "with": [12, 19, 41, 66, 101, 145, 273], "significantly": [13, 159, 291], "increased": [14], "progression-free": [15, 94, 133, 156, 197, 293], "survival": [16, 95, 122, 157, 198, 223, 294], "among": [17], "patients": [18, 40, 65, 97, 137, 150, 272], "recurrent": [20], "ovarian": [21, 45, 70, 277], "cancer": [22, 46, 71, 278], "after": [23, 47, 83], "platinum-based": [24, 52, 87, 284], "chemotherapy,": [25, 285], "regardless": [26, 300], "the": [28, 108, 126, 129, 135, 149, 154, 162, 167, 192, 195, 215, 219, 227, 233, 259, 302], "presence": [29, 303], "or": [30, 79, 180, 252, 304], "absence": [31, 305], "BRCA": [33], "mutations.": [34], "The": [35, 89, 244], "efficacy": [36], "niraparib": [38, 78, 163, 228, 289], "in": [39, 72, 96, 105, 107, 151, 161, 166, 226, 232], "newly": [42, 67, 274], "diagnosed": [43, 68, 275], "advanced": [44, 69, 276], "a": [48, 73, 84, 281], "response": [49, 85, 282], "to": [50, 76, 86, 188, 211, 242, 283], "first-line": [51], "chemotherapy": [53], "is": [54], "unknown.In": [55], "this": [56, 152], "randomized,": [57], "double-blind,": [58], "phase": [59], "3": [60, 251], "trial,": [61], "we": [62], "randomly": [63], "assigned": [64], "2:1": [74], "ratio": [75, 176], "receive": [77], "placebo": [80, 168, 234], "once": [81], "daily": [82], "chemotherapy.": [88], "primary": [90, 130], "end": [91], "point": [92], "was": [93, 123, 158, 199, 224], "who": [98, 138, 279, 287, 297], "had": [99, 143, 280, 290], "tumors": [100, 144], "homologous-recombination": [102, 146, 307], "deficiency": [103], "and": [104, 202, 230, 264], "those": [106, 286, 296], "overall": [109, 121, 193, 222], "population,": [110, 194], "as": [111], "determined": [112], "on": [113], "hierarchical": [114], "testing.": [115], "A": [116], "prespecified": [117], "interim": [118, 217], "analysis": [119, 131], "for": [120, 177], "conducted": [124], "at": [125], "time": [127], "survival.Of": [134], "733": [136], "underwent": [139], "randomization,": [140], "373": [141], "(50.9%)": [142], "deficiency.": [147, 308], "Among": [148], "category,": [153], "median": [155], "longer": [160, 292], "group": [164, 169, 229, 235], "than": [165, 295], "(21.9": [170], "months": [171, 201, 204], "vs.": [172], "10.4": [173], "months;": [174], "hazard": [175], "disease": [178], "progression": [179], "death,": [181], "0.43;": [182], "95%": [183, 208, 239], "confidence": [184], "interval": [185], "[CI],": [186], "0.31": [187], "0.59;": [189], "P<0.001).": [190, 213], "In": [191], "corresponding": [196], "13.8": [200], "8.2": [203], "(hazard": [205, 236], "ratio,": [206, 237], "0.62;": [207], "CI,": [209, 240], "0.50": [210], "0.76;": [212], "At": [214], "24-month": [216], "analysis,": [218], "rate": [220], "84%": [225], "77%": [231], "0.70;": [238], "0.44": [241], "1.11).": [243], "most": [245], "common": [246], "adverse": [247], "events": [248], "grade": [250], "higher": [253], "were": [254], "anemia": [255], "(in": [256, 262, 266], "31.0%": [257], "patients),": [260], "thrombocytopenia": [261], "28.7%),": [263], "neutropenia": [265], "12.8%).": [267], "No": [268], "treatment-related": [269], "deaths": [270], "occurred.Among": [271], "received": [288, 298], "placebo,": [299], "(Funded": [309], "by": [310], "GlaxoSmithKline;": [311], "PRIMA/ENGOT-OV26/GOG-3012": [312], "ClinicalTrials.gov": [313], "number,": [314], "NCT02655016.).": [315]}